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Context Mucinous cystic tumors occur almost exclusively in middle-aged women and in the body or tail of the pancreas. Mucinous 
cystadenocarcinoma, a malignant sub-type of mucinous cystic tumors, in the head of the pancreas and in a middle-aged man is 
extraordinary, and the prognosis and proper management of mucinous cystadenocarcinoma has not been well documented. Case 
report A 52-year-old male patient with a mucinous cystadenocarcinoma approximately 5.5 cm in size in the head of the pancreas 
underwent a total pancreaticoduodenectomy and segmental resection of the superior mesenteric vein-portal vein confluence with an 
autologous splenic vein graft due to tumor invasion. His postoperative course was uneventful and he received adjuvant 
chemotherapy. He has been followed-up periodically for more than 30 months after surgery without evidence of recurrence. 
Conclusion Mucinous cystadenocarcinoma in the head of the pancreas in a middle-aged man is an extremely rare case. Because 
mucinous cystadenocarcinomas have a relatively good prognosis, an aggressive approach with major vascular resection is warranted 
in well-selected patients. Splenic vein interposition grafting could be used in cases which undergo total pancreaticoduodenectomy 




Compagno and Oertel first differentiated between 
microcystic tumors (glycogen-rich serous cystic 
neoplasms) and macrocystic tumors (mucin-producing 
neoplasms) in 1978 [1]. The World Health 
Organization (WHO) classification (1996) [2] and the 
Armed Forces Institute of Pathology (AFIP) 
classification (1997) [3] defined and differentiated 
mucin-producing neoplasms into two types: mucinous 
cystic tumors and intraductal papillary mucinous 
tumors (IPMTs) [4]. According to the WHO and AFIP 
classifications, mucinous cystic tumors are 
characterized by the presence of ovarian-like stroma 
[4]. This ovarian-type stroma helps explain the 
difference between mucinous cystic tumors and other 
pancreatic cystic neoplasms, and their high prevalence 
in females. According to previous reports, mucinous 
cystic tumors occur almost exclusively in middle-aged 
women and in the body or tail of the pancreas [4, 5]. In 
addition, despite the fact that mucinous 
cystadenocarcinoma (high-grade dysplasia), one of the 
several sub-types of mucinous cystic tumors, is 
regarded as malignant, its recurrence rate and incidence 
of metastasis is unpredictable and reported with a wide 
range [5, 6, 7]. Therefore, the prognosis and proper 
management of mucinous cystadenocarcinomas has not 
been well documented. We herein report an 
extraordinary case of mucinous cystadenocarcinoma in 
the head of the pancreas in a middle-aged man. The 
patient underwent a total pancreaticoduodenectomy 
and segmental resection of the superior mesenteric 
vein-portal vein confluence with an autologous splenic 




A 52-year-old male patient was admitted for abdominal 
discomfort and weight loss over the previous year. He 
was a heavy consumer of alcohol and was hospitalized 
with suspicion of a pancreatic pseudocyst with chronic 
pancreatitis without tenderness or palpable mass in his 
abdomen and diabetes mellitus. The results of his 
laboratory investigations were unremarkable except for 
his serum levels of glucose (169 mg/dL; reference 
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range: 70-110 mg/dL), carcinoembryonic antigen (5.37 
ng/mL; reference range: 0-5.00 ng/mL) and 
carbohydrate antigen (CA) 19-9 (210 U/mL; reference 
range: 0-37 U/mL) which were all elevated. Computed 
tomography (CT) revealed aggravation of the cystic 
lesion (about 5.5 cm in size) and diffuse inflammation 
around the pancreatic parenchyma with pancreatic duct 
dilatation (Figure 1a). A magnetic resonance 
cholangiopancreatography (MRCP) demonstrated a 
large unilocular cyst at the head without 
communication with the main pancreatic duct (Figure 
1b). Magnetic resonance imaging (MRI) revealed a 
stenosis of the superior mesenteric vein-portal vein 
junction (Figure 1c). Positron emission tomography 
(PET) showed hypermetabolism at the pancreatic head 
area, suggesting pancreatic cancer (Figure 1d). 
Endoscopic ultrasound (EUS) with fine-needle 
aspiration of the cyst was then performed. 
Histopathological analysis of the cystic fluid revealed 
an atypical epithelium with intracytoplasmic mucin, 
suggestive of mucinous adenocarcinoma (Figure 1e). In 
addition, immunohistochemical analysis of the fluid 
showed that amylase (1,927 U/L reference range: 30-
115 U/L), lipase (13,688 U/L reference range: 5-60 
U/L), carcinoembryonic antigen (925 ng/mL) and CA 
19-9 (more than 20,000 U/mL) levels were all 
extremely high. Based on these findings, we diagnosed 
it as a mucinous cystadenocarcinoma involving the 
pancreatic head and body with superior mesenteric 
vein-portal vein invasion; we then decided to perform a 
total pancreaticoduodenectomy with a possible superior 
mesenteric vein-portal vein confluence resection. 
The patient underwent a total pancreatico-
duodenectomy with splenectomy. The mass seemed to 
invade the superior mesenteric vein-portal vein 
confluence (Figure 2a). Therefore, approximately 8 cm 
of the superior mesenteric vein-portal vein segment 
needed to be resected for a margin-negative resection 
(Figure 2b). The gap between the end of the portal vein 
and the superior mesenteric vein was too wide for a 
direct end-to-end anastomosis. An autologous graft of 
the healthy splenic vein was harvested (Figure 2c) and 
vascular reconstruction was carried out using the 4 cm 
long segment of the harvested splenic vein (Figure 2d). 
The total operating time was 14 hours and blood loss 
was 1,650 mL. 
Figure 1. Preoperative studies. a. CT revealed aggravation of the
cystic lesion (about 5.5 cm size) and diffuse inflammation around the
pancreatic parenchyma with pancreatic duct dilatation. b. MRCP 
demonstrated a large unilocular cyst at the head without
communication with the main pancreatic duct. c. MRI revealed
stenosis of the superior mesenteric vein-portal vein junction (arrow).
d. PET showed hypermetabolism at the pancreatic head area,
suggesting pancreatic cancer. e. Histopathological analysis of the
cystic fluid revealed an atypical epithelium with intracytoplasmic
mucin, suggestive of mucinous adenocarcinoma. 
Figure 2. Operative findings. a. The mass seemed to invade the
superior mesenteric vein-portal vein (SMV/PV) confluence. b.
Approximately 8 cm of the superior mesenteric vein-portal vein
segment needed to be resected for a margin-negative resection. c.
Autologous graft of the healthy splenic vein was harvested. d.
Vascular reconstruction was made using the 4 cm long segment of
the harvested splenic vein. 
PV: portal vein; RV: renal vein; SMA: superior mesenteric artery;
SV: splenic vein 
Figure 3. The permanent pathologic report revealed an invasive
mucinous cystadenocarcinoma. a. Proliferating single layer of 
columnar epithelium with ovarian-like stroma. b. Infiltrating 
irregular dysplastic glands with stromal desmoplasia and irregular 
cell nests. (H&E; original magnification: a. x100; b. x200) 
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The patient returned to an oral diet on the 4th 
postoperative day. The postoperative course was 
uneventful and the patient was discharged on day 14 in 
generally good condition. The permanent pathologic 
report revealed an invasive mucinous cystadeno-
carcinoma with invasion to the common bile duct wall 
and peripancreatic soft tissue with regional lymph node 
metastasis (metastasis of 5 lymph nodes out of the 55 
lymph nodes harvested) (Figure 3). He received UFT 
(tegafur) plus gemcitabine combination adjuvant 
chemotherapy and he is still alive. A follow-up CT at 
the 31st postoperative month showed a patent graft and 




Mucinous cystadenocarcinoma is a malignant form of a 
mucinous cystic neoplasm and is defined as high-grade 
dysplastic mucin-producing columnar epithelium [8]. 
Several findings suggest the premalignant potential of 
mucinous cystadenoma to mucinous cystadeno-
carcinoma. First, mucinous cystic tumors occur as 
several sub-types, classified as mucinous cystadenoma 
(mild epithelial dysplasia), mucinous cystic borderline 
tumors (moderate epithelial dysplasia), and mucinous 
cystadenocarcinomas (high-grade dysplasia) [9]. 
Second, some Authors have reported that the long-term 
follow-up of benign mucinous cystic tumors show 
malignant transformation [10]. Third, mucinous 
cystadenocarcinomas tend to occur in patients 
approximately 15 years older than those with mucinous 
cystadenomas [11]. Finally, the coexistence of benign 
and malignant epithelia in the resected tumors was 
observed [12]. 
Mucinous cystadenocarcinomas show less female 
predominance and occur in the head in 46% of cases, 
according to an analysis of 156 cases with mucinous 
cystadenocarcinomas [10]. Communication with the 
pancreatic duct in mucinous cystadenocarcinomas has 
been reported in several studies [10, 13]. These 
paradoxical features as related to the developmental 
process are difficult to explain. 
Despite the remarkable advancement in technology, 
preoperative imaging studies do not permit a 
differential diagnosis of mucinous cystadenocarcinoma 
from other pancreatic cyst neoplasms, especially 
pseudocysts. Some cytologic and biologic 
investigations can help the diagnosis. Cytologic 
examination can reveal atypical epithelial cells 
containing mucin, but they are frequently 
uninformative [10]. High levels of CEA (greater than 
400 ng/mL) and CA 19-9 (greater than 50,000 U/mL) 
in aspirated cystic fluid show good specificity [10]. In 
our case, the levels of CEA and CA 19-9 in the 
aspirates were 925 ng/mL and greater than 20,000 
U/mL, respectively. The high levels of amylase and 
lipase in the aspirates, such as in our case, suggest the 
presence of communication with the pancreatic duct, 
although all other studies have failed to reveal this 
evidence. Some argue the possible risk of tumor cell 
seeding during fine-needle aspiration. However, no 
tumor cell seeding has been reported and the 
misdiagnosis of a pseudocyst can lead to inappropriate 
treatment of mucinous cystadenocarcinoma [10]. In 
this regard, exhaustive efforts are necessary in order to 
reach the exact diagnosis. 
After the establishment of a diagnosis, aggressive and 
complete surgical approaches are warranted since 
mucinous cystadenocarcinomas show a better 
prognosis than the more common pancreatic ductal 
adenocarcinomas. The 5-year survival rate reaches 50-
72% for resected mucinous cystadenocarcinomas [10, 
14, 15]. However, unless a mucinous cystadeno-
carcinoma is resected, the prognosis is as dismal as that 
for unresected ductal adenocarcinoma [7, 12]. And 
lymph node involvement is less common for mucinous 
cystadenocarcinoma (36%) than for ductal 
adenocarcinoma (69%) [16]. Finally, the curative 
resection rate is as high as 65-74% in several surveys 
[10, 15]. According to Sarr et al. mucinous 
cystadenocarcinomas tend to grow by pushing adjacent 
structures rather than by invading them [17]. However, 
as in our case, the tumor can invade the surrounding 
structures and, even in such circumstances, an 
aggressive resection including the structures invaded is 
warranted [10]. 
In particular, a more aggressive en-bloc pancreatico-
duodenectomy including superior mesenteric vein-
portal vein resection has recently been performed with 
decreased surgical complications due to improvement 
in the surgical technique and postoperative 
management [18]. The resected portal tract can be 
reconstructed with a direct end-to-end anastomosis 
when the length of resection is adequate to provide a 
tension-free anastomosis. But larger segments of 
resection need a graft for reconstruction with a 
saphenous vein, an iliac vein, an internal jugular vein 
or a synthetic vascular prosthesis [18, 19]. In our case, 
we used splenic vein interposition grafting exclusively 
because there was no evidence of tumor invasion into 
Figure 4. A follow-up CT at the 31st postoperative month showed a 
patent graft (arrow) and no evidence of recurrence. 
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the splenic vein and it was already included in the 
specimen. 
In summary, even though mucinous cyst-
adenocarcinomas can have diverse clinicopathological 
features, its presence in male patients and in the 
pancreatic head is extremely rare. Therefore, it is 
important to make an exact diagnosis in order to 
determine and provide the proper management. Since 
mucinous cystadenocarcinoma has a relatively good 
prognosis, an aggressive surgical approach with major 
vascular resection is warranted in well-selected 
patients. Splenic vein interposition grafting could be 
used in the cases which undergo a total 
pancreaticoduodenectomy with resection of superior 
mesenteric vein-portal vein confluence, if the splenic 
vein is healthy. 
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